Quetiapine

Quetiapine is a second-generation antipsychotic, a class of drugs developed to treat psychosis with a lower tendency to cause the movement side effects associated with the older, first-generation agents ^[1][2]. Chemically it is a tetracyclic compound related to clozapine and olanzapine, with the molecular formula C21H25N3O2S, and it is usually dispensed as the fumarate salt ^[1]. It is taken by mouth and, once absorbed, is broken down in the liver, partly into an active metabolite called norquetiapine that contributes to its effects ^[1].

The drug was developed in the 1980s and first approved by the United States Food and Drug Administration in 1997 under the brand name Seroquel, made by AstraZeneca ^[1]. An extended-release version followed in the late 2000s, and after patent protection ended the medicine became widely available as a generic ^[1]. It is listed among the World Health Organization's essential medicines and is one of the most frequently prescribed antipsychotics ^[2].

Quetiapine is approved for schizophrenia, for the manic, depressive, and maintenance phases of bipolar disorder, and as an add-on treatment for major depressive disorder that has not responded to an antidepressant alone ^[1]. Reviews of clinical trials support its usefulness across these indications; in bipolar depression, for example, controlled studies found it more effective than placebo at reducing depressive symptoms and at preventing relapse ^[1]. In a large comparative meta-analysis of antipsychotics for schizophrenia, quetiapine was among the effective agents, occupying a middle position for efficacy while differing from other drugs in its particular pattern of side effects ^[2]. Beyond its licensed uses, it is very commonly prescribed off-label at low doses for insomnia and anxiety, although clinical guidance generally advises against using it for sleep because the risks are felt to outweigh the modest benefit ^[1].

Quetiapine is a prescription-only medicine available as immediate-release and extended-release oral tablets ^[1]. Like other antipsychotics it carries regulatory warnings, including an increased risk of death when used in elderly people with dementia-related psychosis and a caution about suicidal thoughts in younger patients taking antidepressant-class treatments ^[1]. Its comparatively broad receptor activity gives it a distinctive profile of both benefits, such as a low rate of movement disorders, and drawbacks, such as sedation and weight gain ^[1][3].

Quetiapine is prescription only and carries a boxed warning about increased death rates when used for dementia-related psychosis in the elderly, plus the class warning about suicidal thoughts in younger people with depression. The most common effects are strong sedation, dizziness on standing from the blood pressure drop, dry mouth, and constipation. Over time it can cause weight gain, higher blood sugar, and raised cholesterol, though generally less than olanzapine, so metabolic monitoring is advised. It can prolong the heart's QT interval, and rare but serious risks include neuroleptic malignant syndrome, tardive dyskinesia, and cataracts with long use. Doses should be tapered rather than stopped abruptly to avoid rebound insomnia and nausea.

Quetiapine is cleared almost entirely by CYP3A4, and that single route explains most of its interactions. Strong inhibitors such as ketoconazole, itraconazole, clarithromycin and ritonavir cut its clearance sharply and can raise plasma levels several-fold, bringing out sedation, orthostatic hypotension and QT effects. Inducers push the other way: phenytoin raised quetiapine clearance about fivefold in pharmacokinetic study, and carbamazepine, rifampin and St John's wort act similarly, which can leave the antipsychotic effect gone with no obvious cause.

Quetiapine modestly prolongs the QT interval, so pairing it with class IA or class III antiarrhythmics, methadone, or other QT-prolonging antipsychotics compounds torsades risk, particularly when potassium or magnesium is low.

The pharmacodynamic overlaps are the quiet ones. Alcohol, benzodiazepines and opioids add to its sedation and respiratory depression, and its alpha-1 blockade stacks with antihypertensives to produce fainting on standing. Quetiapine itself inhibits no major cytochrome at clinical concentrations, so it rarely disturbs other drugs.

Checking a whole stack? Run it through interactions + stacks.

Quetiapine was developed by the pharmaceutical company Zeneca, later part of AstraZeneca, with the core molecule first synthesized in the mid 1980s as part of a search for antipsychotics that would spare patients the movement side effects of the older typical agents. It received approval from the United States Food and Drug Administration in 1997 and was marketed as Seroquel, with an extended-release formulation, Seroquel XR, following in 2007.

Its therapeutic profile was progressively expanded from schizophrenia to acute bipolar mania and depression and, later, to adjunctive treatment of major depressive disorder, reflecting the discovery that its active metabolite norquetiapine contributes distinct antidepressant activity. Once its patents expired the drug became widely available as an inexpensive generic and was added to the World Health Organization Model List of Essential Medicines. Today quetiapine is one of the most prescribed second-generation antipsychotics worldwide, though its heavy off-label use for insomnia has drawn cautionary commentary from clinicians.

Quetiapine enjoys a reputation as one of the most versatile agents in psychiatry, valued for a genuinely broad evidence base spanning schizophrenia, both poles of bipolar disorder, and treatment-resistant depression. It is well regarded for causing little of the prolactin elevation and few of the movement disturbances associated with older antipsychotics, a consequence of its characteristically loose and transient binding to the dopamine D2 receptor.

Large network meta-analyses consistently place quetiapine among the effective and reasonably tolerated options for acute mania, reinforcing its standing as a dependable mood stabilizer. Its marked sedative quality, from strong histamine H1 blockade, is prized by many patients who struggle with agitation and sleep, even as clinicians caution against using it purely as a sleep aid. Honestly, its main limitations are metabolic: weight gain, sedation, and orthostatic effects mean it is a drug to be dosed thoughtfully rather than casually.